Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Pulmonx (NASDAQ:LUNG), un'azienda specializzata in trattamenti minimamente invasivi per le malattie polmonari, ha annunciato la sua partecipazione alla prossima Canaccord Genuity 45陋 Conferenza Annuale sulla Crescita. La presentazione 猫 prevista per il 12 agosto 2025, alle 7:00 AM PT / 10:00 AM ET a Boston.
Investitori e parti interessate possono accedere sia alla presentazione in diretta che alla registrazione webarchivio tramite la sezione relazioni con gli investitori del sito web di Pulmonx all'indirizzo investors.pulmonx.com.
Pulmonx (NASDAQ:LUNG), una empresa especializada en tratamientos m铆nimamente invasivos para enfermedades pulmonares, ha anunciado su participaci贸n en la pr贸xima Conferencia Anual de Crecimiento n煤mero 45 de Canaccord Genuity. La presentaci贸n est谩 programada para el 12 de agosto de 2025, a las 7:00 AM PT / 10:00 AM ET en Boston.
Los inversores y partes interesadas pueden acceder tanto a la presentaci贸n en vivo como a la transmisi贸n archivada a trav茅s de la secci贸n de relaciones con inversores del sitio web de Pulmonx en investors.pulmonx.com.
Pulmonx (NASDAQ:LUNG)電� 斓滌唽 旃姷 韽� 歆堩櫂 旃橂毳� 鞝勲鞙茧 頃橂姅 須岇偓搿�, 雼り皜鞓る姅 Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 氚滍憸電� 2025雲� 8鞗� 12鞚� 鞓れ爠 7鞁� PT / 鞓れ爠 10鞁� ET 氤挫姢韯挫棎靹� 歆勴枆霅╇媹雼�.
韴瀽鞛� 氚� 甏�鞁� 鞛堧姅 攵勲摛鞚� Pulmonx 鞗轨偓鞚错姼鞚� 韴瀽鞛� 甏�瓿� 靹轨厴 investors.pulmonx.com鞚� 韱淀暣 靸濎瓿� 氚滍憸鞕� 鞎勳勾鞚措笇 鞗轨簮鞀ろ姼毳� 氇憪 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Pulmonx (NASDAQ:LUNG), une entreprise sp茅cialis茅e dans les traitements mini-invasifs des maladies pulmonaires, a annonc茅 sa participation 脿 la 45e conf茅rence annuelle sur la croissance de Canaccord Genuity. La pr茅sentation est pr茅vue pour le 12 ao没t 2025 脿 7h00 PT / 10h00 ET 脿 Boston.
Les investisseurs et les parties int茅ress茅es peuvent acc茅der 脿 la fois 脿 la pr茅sentation en direct et au webdiffus茅 archiv茅 via la section relations investisseurs du site web de Pulmonx 脿 l'adresse investors.pulmonx.com.
Pulmonx (NASDAQ:LUNG), ein Unternehmen, das sich auf minimalinvasive Behandlungen von Lungenerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 45. j盲hrlichen Wachstums-Konferenz von Canaccord Genuity angek眉ndigt. Die Pr盲sentation ist f眉r den 12. August 2025, um 7:00 Uhr PT / 10:00 Uhr ET in Boston geplant.
Investoren und Interessierte k枚nnen sowohl die Live-Pr盲sentation als auch das archivierte Webcast 眉ber den Investor-Relations-Bereich der Pulmonx-Website unter investors.pulmonx.com abrufen.
- None.
- None.
REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (鈥淧ulmonx鈥� or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET.
A live and archived webcast of the presentation will be available on 鈥淚nvestors鈥� section of the Pulmonx website at聽.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx鈥檚 Zephyr庐 Endobronchial Valve, Chartis庐 Pulmonary Assessment System, LungTraXTM Platform, and StratX庐 Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a 鈥渂reakthrough device.鈥� The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx庐, AeriSeal庐, Chartis庐, StratX庐, and Zephyr庐 are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
FAQ
When is Pulmonx (LUNG) presenting at the Canaccord Genuity Growth Conference?
How can investors access Pulmonx's (LUNG) presentation at the Canaccord conference?
What does Pulmonx (LUNG) specialize in?
Where is the Canaccord Genuity Growth Conference being held?
